MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Atypical presentation of Pantothenate Kinase-Associated Neurodegeneration in two siblings with a PANK-2 gene mutation: A case report and literature review.

H. Pacheco, V. Gómez, L. Núñez (Mexico, Mexico)

Meeting: 2025 International Congress

Keywords: Dystonia: Clinical features, Dystonia: Genetics, Dystonia: Treatment

Category: Dystonia: Epidemiology, phenomenology, clinical assessment, rating scales

Objective: To describe the cases of two siblings diagnosed with Pantothenate Kinase-Associated Neurodegeneration (PKAN) with mutations in the PANK2 gene.

Background: PKAN is part of a group of iron accumulation disorders in the basal ganglia (BG) due to a mutation in the PANK-2 gene, resulting in an inherited metabolic error of vitamin B5, which is essential for the production of coenzyme A. This leads to abnormal accumulation of compounds such as iron in brain structures. Clinically, it presents with dystonia, cognitive dysfunction, pyramidal signs, and retinal abnormalities. Magnetic Resonance Imaging (MRI) reveals the characteristic “tiger eye” sign, and treatment includes medications, botulinum toxin, and deep brain stimulation (DBS) surgery.

Method: Demographic information and clinical characteristics of patients are summarized in table 1. History of both originating from and residing in Michoacán, México, with no consanguinity, endogamy, or family history. Age of onset was <20 years in both cases.

Results: Genetic study revealed 3 mutations (c.332T>A, c.1211A>T, and c.1405G>C) in heterozygosity and 1 mutation (c.377G>C) in homozygosity of the PANK2 gene. MRI showing “tiger eye” sign in the globus pallidus of both patients (Image 1 A and B). Treatment with botulinum toxin showed no improvement. Placement of DBS in July 2024 (♂STN and ♀GPi). Unified Dystonia Rating Scale (UDRS), post-botulinum toxin application, and post-DBS placement, with improvement of ♂ 11% and ♀ 63% (Graphic 1).

Conclusion: PKAN is an uncommon entity. Both patients exhibited an atypical presentation, with a disease course exceeding 15 years without neuropsychiatric, cognitive, or ophthalmological alterations, and were refractory to treatment with botulinum toxin. In these cases, DBS represented a useful therapeutic option for the improvement of motor symptoms.

Table 1. Demographic information

Table 1. Demographic information

Image 1. RM (19.07.24) A ♂ 33 y. B♀28 y.

Image 1. RM (19.07.24) A ♂ 33 y. B♀28 y.

Graphic 1

Graphic 1

To cite this abstract in AMA style:

H. Pacheco, V. Gómez, L. Núñez. Atypical presentation of Pantothenate Kinase-Associated Neurodegeneration in two siblings with a PANK-2 gene mutation: A case report and literature review. [abstract]. Mov Disord. 2025; 40 (suppl 1). https://www.mdsabstracts.org/abstract/atypical-presentation-of-pantothenate-kinase-associated-neurodegeneration-in-two-siblings-with-a-pank-2-gene-mutation-a-case-report-and-literature-review/. Accessed October 5, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2025 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/atypical-presentation-of-pantothenate-kinase-associated-neurodegeneration-in-two-siblings-with-a-pank-2-gene-mutation-a-case-report-and-literature-review/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Insulin dependent diabetes and hand tremor
  • Improvement in hand tremor following carpal tunnel release surgery
  • Impact of expiratory muscle strength training (EMST) on phonatory performance in Parkinson's patients
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley